DOI QR코드

DOI QR Code

Analgesic effect of quetiapine in a mouse model of cancer-induced bone pain

  • Heo, Mi Hwa (Department of Internal Medicine, Keimyung University Dongsan Medical Center) ;
  • Kim, Jin Young (Department of Internal Medicine, Keimyung University Dongsan Medical Center) ;
  • Hwang, Ilseon (Department of Pathology, Keimyung University Dongsan Medical Center) ;
  • Ha, Eunyoung (Department of Pain Research Center, Keimyung University Dongsan Medical Center) ;
  • Park, Keon Uk (Department of Internal Medicine, Keimyung University Dongsan Medical Center)
  • Received : 2015.11.23
  • Accepted : 2016.10.06
  • Published : 2017.11.01

Abstract

Background/Aims: Cancer-induced bone pain (CIBP) is one of the most common pains in patients with advanced neoplasms. Because of treatment-associated side effects, more than half of cancer patients are reported to have inadequate and undermanaged pain control. New mechanism-based therapies must be developed to reduce cancer pain. Quetiapine is a commonly used atypical antipsychotic drug. We report a study of the potential analgesic effects of quetiapine in a mouse model of CIBP and examine the mechanism of bone pain by analyzing the expression of various nociceptors. Methods: Fifteen male C3H/HeN mice were arbitrarily divided into five groups: control and, CIBP with no treatment, quetiapine treatment, opioid treatment, and melatonin treatment. The mice were tested for mechanical hyperalgesia by determining the nociceptive hind paw withdrawal pressure threshold. Tissues from tibia were removed and subjected to quantitative and qualitative evaluations of transient receptor potential vanilloid 1 (TRPV1), TRPV4, acid-sensing ion channel 1 (ASIC1), ASIC2, and ASIC3 expression. Results: Paw withdrawal pressure threshold was improved in the quetiapine treatment group compared with the CIBP group. Expression of TRPV1, TRPV4, ASIC1, ASIC2, and ASIC3 in the CIBP with quetiapine treatment group was significantly lower than that in the CIBP group. Conclusions: Our results suggest an analgesic effect of quetiapine in the CIBP animal model and implicate TRPV and ASICs as potential targets for cancer pain management.

Keywords

Acknowledgement

Supported by : Keimyung University Kidney Institute

References

  1. Goudas LC, Bloch R, Gialeli-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain. Cancer Invest 2005;23:182-190. https://doi.org/10.1081/CNV-50482
  2. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695-1700. https://doi.org/10.1016/S0140-6736(99)01310-0
  3. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-1132. https://doi.org/10.1056/NEJM199610103351507
  4. de Wit R, van Dam F, Loonstra S, et al. The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain. Pain 2001;91:339-349. https://doi.org/10.1016/S0304-3959(00)00455-3
  5. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001;93:247-257. https://doi.org/10.1016/S0304-3959(01)00324-4
  6. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886-10897. https://doi.org/10.1523/JNEUROSCI.19-24-10886.1999
  7. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002;2:201-209. https://doi.org/10.1038/nrc747
  8. Fujii Y, Ozaki N, Taguchi T, Mizumura K, Furukawa K, Sugiura Y. TRP channels and ASICs mediate mechanical hyperalgesia in models of inflammatory muscle pain and delayed onset muscle soreness. Pain 2008;140:292-304. https://doi.org/10.1016/j.pain.2008.08.013
  9. Ikeuchi M, Kolker SJ, Burnes LA, Walder RY, Sluka KA. Role of ASIC3 in the primary and secondary hyperalgesia produced by joint inflammation in mice. Pain 2008;137:662-669. https://doi.org/10.1016/j.pain.2008.01.020
  10. Xu TL, Duan B. Calcium-permeable acid-sensing ion channel in nociceptive plasticity: a new target for pain control. Prog Neurobiol 2009;87:171-180. https://doi.org/10.1016/j.pneurobio.2009.01.004
  11. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001;413:203-210. https://doi.org/10.1038/35093019
  12. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo: the Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246. https://doi.org/10.1016/S0006-3223(97)00190-X
  13. Bianchi M, Panerai AE. Antidepressant drugs and experimental inflammation. Pharmacol Res 1996;33:235-238. https://doi.org/10.1006/phrs.1996.0032
  14. Taler M, Bar M, Korob I, et al. Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders. Int Immunopharmacol 2008;8:526-533. https://doi.org/10.1016/j.intimp.2007.12.003
  15. Kim H, Bang J, Chang HW, et al. Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur J Pharmacol 2012;678:55-60. https://doi.org/10.1016/j.ejphar.2011.12.017
  16. Lozano-Ondoua AN, Symons-Liguori AM, Vanderah TW. Cancer-induced bone pain: mechanisms and models. Neurosci Lett 2013;557 Pt A:52-59. https://doi.org/10.1016/j.neulet.2013.08.003
  17. Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Res 1994;654:15-26. https://doi.org/10.1016/0006-8993(94)91566-0
  18. Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW. Bone cancer pain. Ann N Y Acad Sci 2010;1198:173-181. https://doi.org/10.1111/j.1749-6632.2009.05429.x
  19. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006;7:797-809. https://doi.org/10.1038/nrn1914
  20. Zhang RX, Liu B, Wang L, et al. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 2005;118:125-136. https://doi.org/10.1016/j.pain.2005.08.001

Cited by

  1. Recent advances in understanding and managing cancer pain vol.6, pp.None, 2017, https://doi.org/10.12688/f1000research.10817.1
  2. Letter to the Editor: “Ion Channels in Brain Metastasis”—Ion Channels in Cancer Set up and Metastatic Progression vol.18, pp.4, 2017, https://doi.org/10.3390/ijms18040718
  3. microRNA-329 reduces bone cancer pain through the LPAR1-dependent LPAR1/ERK signal transduction pathway in mice vol.11, pp.None, 2019, https://doi.org/10.1177/1758835919875319
  4. Analgesic effects of microRNA‐129‐5p against bone cancer pain through the EphB1/EphrinB2 signaling pathway in mice vol.120, pp.3, 2019, https://doi.org/10.1002/jcb.26605
  5. Osteolytic metastasis in breast cancer: effective prevention strategies vol.20, pp.9, 2017, https://doi.org/10.1080/14737140.2020.1807950
  6. Metformin Attenuates Bone Cancer Pain by Reducing TRPV1 and ASIC3 Expression vol.12, pp.None, 2017, https://doi.org/10.3389/fphar.2021.713944